Business Description
Stoke Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US86150R1077
Total Employee Number:
170Description
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 141.2 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 23.45 | |||||
Beneish M-Score | 50.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 113.7 | |||||
3-Year EBITDA Growth Rate | 50.6 | |||||
3-Year EPS without NRI Growth Rate | 64.1 | |||||
3-Year Book Growth Rate | 8.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -127.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.55 | |||||
9-Day RSI | 56.45 | |||||
14-Day RSI | 56.16 | |||||
3-1 Month Momentum % | -9.32 | |||||
6-1 Month Momentum % | -7.66 | |||||
12-1 Month Momentum % | 163.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.99 | |||||
Quick Ratio | 8.99 | |||||
Cash Ratio | 8.42 | |||||
Days Sales Outstanding | 74.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.3 | |||||
Shareholder Yield % | -3.94 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -577.46 | |||||
Net Margin % | -529.2 | |||||
EBITDA Margin % | -572.06 | |||||
FCF Margin % | -460.04 | |||||
OCF Margin % | -457.33 | |||||
ROE % | -48.77 | |||||
ROA % | -42.16 | |||||
ROIC % | -173.46 | |||||
3-Year ROIIC % | 78.16 | |||||
ROC (Joel Greenblatt) % | -2812.84 | |||||
ROCE % | -51.76 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 67.07 | |||||
PS Ratio | 61.15 | |||||
PB Ratio | 5.2 | |||||
Price-to-Tangible-Book | 5.21 | |||||
EV-to-EBIT | -9.26 | |||||
EV-to-EBITDA | -9.35 | |||||
EV-to-Forward-EBITDA | -8.14 | |||||
EV-to-Revenue | 53.47 | |||||
EV-to-Forward-Revenue | 80.86 | |||||
EV-to-FCF | -11.61 | |||||
Price-to-GF-Value | 3.26 | |||||
| Price-to-Net-Current-Asset-Value | 6.46 | |||||
| Price-to-Net-Cash | 6.96 | |||||
Earnings Yield (Greenblatt) % | -10.8 | |||||
FCF Yield % | -7.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Stoke Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 27.622 | ||
| EPS (TTM) (€) | -2.438 | ||
| Beta | 1.7049 | ||
| 3-Year Sharpe Ratio | 0.76 | ||
| 3-Year Sortino Ratio | 1.66 | ||
| Volatility % | 55.03 | ||
| 14-Day RSI | 56.16 | ||
| 14-Day ATR (€) | 0.501338 | ||
| 20-Day SMA (€) | 26.735 | ||
| 12-1 Month Momentum % | 163.54 | ||
| 52-Week Range (€) | 9.8 - 32.8 | ||
| Shares Outstanding (Mil) | 62.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Stoke Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Stoke Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 35 days | ||
| Guidance call for 2026 | 2026-06-08 10:40 | 25.30 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-04 09:20 | 24.23 (+0.00%) | ||
| General meeting for 2026 | 2026-06-03 09:00 | 25.67 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 27.72 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 27.72 (+0.00%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 15:00 | 28.70 (+0.00%) |
Show
Entries
Stoke Therapeutics Inc Frequently Asked Questions
What is Stoke Therapeutics Inc(FRA:0GT)'s stock price today?
The current price of FRA:0GT is €27.72. The 52 week high of FRA:0GT is €32.80 and 52 week low is €9.80.
When is next earnings date of Stoke Therapeutics Inc(FRA:0GT)?
The next earnings date of Stoke Therapeutics Inc(FRA:0GT) is 2026-08-12 Est..
Does Stoke Therapeutics Inc(FRA:0GT) pay dividends? If so, how much?
Stoke Therapeutics Inc(FRA:0GT) does not pay dividend.
Press Release
Articles on Stoke Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers